Retatrutide and trizepatide are a novel class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor agonists display exceptional therapeutic benefits in the management of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection,